Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Enanta Pharmaceuticals Inc ENTA

Healthcare Biotechnology

Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered... see more

Add To Watchlist

Recent & Breaking News (NDAQ:ENTA)

RDInvesting Provides Investors with Free In-Depth Equity Reports on BCRX, ENTA, IDIX and RPTP

Accesswire January 29, 2014

Enanta Pharmaceuticals Initiates Phase 1 Study of MRSA Infection Candidate EDP-788

Business Wire January 13, 2014

Enanta Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference

Business Wire January 6, 2014

Wall Street Fundamentals Releases New In-Depth Stock Reports on CMRX, ENTA, OPHT and PTLA

Accesswire December 11, 2013

TrendingWallStreet.com Presents Trend Coverage on ENTA, VUZI, BBRY, and YGE

Accesswire December 11, 2013

Enanta Pharmaceuticals Announces 96 Percent SVR12 in Treatment Experienced Genotype 1 Hepatitis C Patients in SAPPHIRE-II Study

Business Wire December 10, 2013

Enanta Pharmaceuticals to Present at the Deutsche Bank 2013 BioFest

Business Wire November 25, 2013

Enanta Pharmaceuticals Announces the Appointment of Bruce L.A. Carter, Ph.D. to Board of Directors

Business Wire November 25, 2013

Enanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for the Fiscal Fourth Quarter and Year Ended September 30, 2013

Business Wire November 15, 2013

New GT-1b Data from ABT-450 Containing Regimen Being Presented at The Liver Meeting

Business Wire November 3, 2013

Enanta Announces New Data on ABT-450 Regimens to be Presented at The Liver Meeting (AASLD)

Business Wire October 1, 2013

Enanta Pharmaceuticals Announces National Institute of Allergy and Infectious Diseases (NIAID) Will Fund Further Development of a Novel Bicyclolide

Business Wire September 3, 2013

Enanta Pharmaceuticals to Present at Upcoming Investor Conferences

Business Wire August 28, 2013

Enanta Pharmaceuticals Reports Financial Results for the Third Fiscal Quarter and Nine Months Ended June 30, 2013

Business Wire August 12, 2013

Enanta Pharmaceuticals, Inc. [ENTA] Celebrates Their Recent IPO and Recognizes World Hepatitis Day by Ringing The NASDAQ Stock Market Opening Bell

Globe Newswire July 25, 2013

Enanta Pharmaceuticals Added to the Russell 3000® and Russell 2000® Indexes

Business Wire July 1, 2013

Enanta Pharmaceuticals to Present at the 8th Annual JMP Securities Healthcare Conference

Business Wire July 1, 2013

Enanta Pharmaceuticals to Present at the Wells Fargo Securities 2013 Healthcare Conference

Business Wire June 14, 2013

Enanta Pharmaceuticals to Present at Upcoming Investor Conferences

Business Wire May 28, 2013

Enanta Pharmaceuticals Announces Financial Results for the Second Fiscal Quarter and Six Months Ended March 31, 2013

Business Wire May 8, 2013